NCT05535933View on ClinicalTrials.gov

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

November 30, 2026

Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
DRUG

HMPL-523(300mg PO QD)

HMPL-523(300mg PO QD)

DRUG

Placebo

Placebo(300mg PO QD)

Trial Locations (5)

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Lanzhou

RECRUITING

The First affiliated hospital of nanchang uiversity, Nanchang

RECRUITING

Bethune First Hospital Of Jilin University, Changchun

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY